Journal: bioRxiv

Article Title: Loss of mutually protective effects between osteoclasts and chondrocytes in damaged joints drives osteoclast-mediated cartilage degradation via matrix metalloproteinases

doi: 10.1101/2021.01.03.425116

Figure Lengend Snippet: (a,b) Effect of bafilomycin, E64 and GM6001 on osteoclast-mediated release of GAG from (a) acellular or (b) cellular cartilage after 13 days of differentiation. N varies for each graph, as represented by the number of data points. (c) Effect of recombinant human TIMP1 (100 nm) on GAG release from osteoclasts cultured on acellular cartilage, n=18. *, p<0.05; ***, p<0.0001.

Article Snippet: For inhibitor experiments, mature osteoclasts were treated with bafilomycin (Cell Signalling Technology, Hitchin, UK), E64 (Cambridge Bioscience, Cambridge, UK), GM6001 (Selleckchem, Munich, Germany) or recombinant human TIMP1 (R&D Systems).

Techniques: Recombinant, Cell Culture

Journal: Cancer Research

Article Title: LOXL2-Mediated Matrix Remodeling in Metastasis and Mammary Gland Involution

doi: 10.1158/0008-5472.can-10-2868

Figure Lengend Snippet: Figure 4. LOXL2 regulates TIMP1. A, Western blot analysis of LOXL2 protein expression and TIMP1 in concentrated CM from 4T1/MDA-MB-231 cells expressing control or LOXL2 shRNA constructs, or transfected with siLOXL2 (compared with mock-transfected control). B, immunofluorescent images of tumor sections from mice bearing 4T1/MDA-MB-231 control or shLOXL2 tumors stained with TIMP1 (green) and 40,6-diamidino-2-phenylindole (DAPI; blue). Scale bar, 100 mm. C, quantification of MDA-MB-231 control or siLOXL2 breast cancer cells þ/ recombinant human TIMP1 invading through matrigel towards a chemoattractant. *P < 0.05. D, invasive branching structures formed by MDA-MB-231control or siLOXL2 cells grown in 3D Matrigel, treated recombinant human TIMP1. Scale bar, top; 500 mm, bottom; 200 mm.

Article Snippet: The gels were transferred to polyvinylidene difluoride membranes (Millipore) and probed with antibodies specific to human LOXL2, TIMP1, b-actin (Abcam), mouse LOXL2 (Santa Cruz Biotechnology Inc.), or TIMP1 (R&D Systems).

Techniques: Western Blot, Expressing, Control, shRNA, Construct, Transfection, Staining, Recombinant

Journal: Cancer Research

Article Title: LOXL2-Mediated Matrix Remodeling in Metastasis and Mammary Gland Involution

doi: 10.1158/0008-5472.can-10-2868

Figure Lengend Snippet: Figure 5. High LOXL2 expression and activity during mammary gland involution. A, qRT-PCR analysis of LOXL2 mRNA expression levels in FVB mouse mammary gland samples at different stages of development (wV ¼ week virgin, dP ¼ day pregnancy, dL ¼ day lactation, dI ¼ day involution). n ¼ 3 mice per time point. * P < 0.05. B, Western blot analysis of LOXL2 and TIMP1 protein expression in lysates prepared from mice in (A). C, LOXL2 enzymatic activity in blood serum from mice in (A). n ¼ 3 mice per time point.

Article Snippet: The gels were transferred to polyvinylidene difluoride membranes (Millipore) and probed with antibodies specific to human LOXL2, TIMP1, b-actin (Abcam), mouse LOXL2 (Santa Cruz Biotechnology Inc.), or TIMP1 (R&D Systems).

Techniques: Expressing, Activity Assay, Quantitative RT-PCR, Western Blot